![]() |
|
|
Vol. 30, Issue 7, 778-787, July 2002
3-Adrenergic Receptor, in Rats:
Identification of a Novel Isethionic Acid Conjugate
Department of Drug Metabolism (W.T., R.A.S., R.R.M., J.S.N.,
G.Y.K., J.R.S., C.A.K., G.A.D., S-H.L.C., T.A.B.) and Medicinal
Chemistry (R.J.M., A.E.W.), Merck Research Laboratories, Rahway, New
Jersey.
(R)-N-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]- 4-[4-(4-trifluoro-methylphenyl)thiazol-2-yl]benzenesulfonamide (1) is a potent and selective agonist of the human
3-adrenergic receptor. We report herein the
data from studies of the metabolism and excretion of 1 in
rats. Five metabolites were identified in the bile of male
Sprague-Dawley rats administered 3H-labeled
1 by either oral gavage (10 mg/kg) or intravenous
injection (3 mg/kg). These included a pyridine N-oxide
derivative (M2), a primary amine resulting from
N-dealkylation and loss of the pyridinyl-2-hydroxyethyl
group (M4), a carboxylic acid derived from N-dealkylation
and loss of the pyridyl-2-hydroxyethyl amine (M5), and the
corresponding taurine and isethionic acid conjugates (M1 and M3).
Metabolites M1 and M3 also were identified in rats treated with M5 and
were generated in incubations of M5 with rat liver subcellular
fractions in the presence of ATP and coenzyme A with supplementary
taurine or isethionic acid. These results suggest that M5 is the
precursor of M1 and M3 and that the formation of these conjugated
metabolites follows similar mechanisms of amino acid conjugation. On
the other hand, M2, M4, and M5 were produced from 1 in an
NADPH-dependent manner in incubations with liver microsomes from rats,
dogs, monkeys, and humans. In human liver preparations, these routes of
biotransformation were shown to be catalyzed by cytochrome P450 3A4. In
a bidirectional transport assay, transport of 1 across a
monolayer of cells expressing P-glycoprotein (Pgp) was observed to be
similar to that of vinblastine, which is an established substrate of
the transporter protein. This finding, together with the observation
that the parent compound was excreted in the feces of bile
duct-cannulated animals following intravenous dosing, suggests that
1 is subject to Pgp-mediated excretion from intestine of
rats.
This article has been cited by other articles:
![]() |
M. R. Anari, M. D. Creighton, J. S. Ngui, R. A. Tschirret-Guth, Y. Teffera, G. A. Doss, W. Tang, N. X. Yu, S. L. Ciccotto, D. F. Hobra Jr., et al. SPECIES DIFFERENCES IN METABOLISM AND PHARMACOKINETICS OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST IN RATS AND DOGS: FORMATION OF A UNIQUE GLUTATHIONE ADDUCT IN THE RAT Drug Metab. Dispos., August 1, 2006; 34(8): 1367 - 1375. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Stearns, R. R. Miller, W. Tang, G. Y. Kwei, F. S. Tang, R. J. Mathvink, E. M. Naylor, D. Chitty, V. J. Colandrea, A. E. Weber, et al. The Pharmacokinetics of a Thiazole Benzenesulfonamide beta 3-Adrenergic Receptor Agonist and Its Analogs in Rats, Dogs, and Monkeys: Improving Oral Bioavailability Drug Metab. Dispos., July 1, 2002; 30(7): 771 - 777. [Abstract] [Full Text] [PDF] |
||||